| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/11/2004 | WO2004020404A2 Modified transferin-antibody fusion proteins |
| 03/11/2004 | WO2004020014A2 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 03/11/2004 | WO2004019994A1 Ark5 |
| 03/11/2004 | WO2004019991A2 Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
| 03/11/2004 | WO2004019983A1 Method of degrading transcriptional factors of saccharometabolism-associated gene, method of inhibiting the degradation and degradation inhibitor |
| 03/11/2004 | WO2004019973A1 Use of protein kinase n beta |
| 03/11/2004 | WO2004019972A1 Use of erythopoietin |
| 03/11/2004 | WO2004019971A1 Antiallergic agent |
| 03/11/2004 | WO2004019970A2 Glycopeptide antibiotic and semisynthetic derivatives thereof and their use as antiviral agents |
| 03/11/2004 | WO2004019969A1 The synergistic effect of the osteogenic growth peptide and the granulocyte colony stimulating factor on haematogenesis |
| 03/11/2004 | WO2004019968A1 Methods for preserving organs and tissues |
| 03/11/2004 | WO2004019967A1 Method for isolating subpopulations of proteins that engage in protein-protein interactions |
| 03/11/2004 | WO2004019965A2 Thymus-based tolerogenic approaches for type i diabetes. |
| 03/11/2004 | WO2004019961A1 Plant extracts for treatment of angiogenesis and metastasis |
| 03/11/2004 | WO2004019936A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions |
| 03/11/2004 | WO2004019921A2 Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| 03/11/2004 | WO2004019912A2 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 03/11/2004 | WO2004019911A2 Buccal, polar or non-polar spray or capsule containing drugs for treating endocrine disorders |
| 03/11/2004 | WO2004019910A2 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 03/11/2004 | WO2004019909A2 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 03/11/2004 | WO2004019905A1 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 03/11/2004 | WO2004019904A1 Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
| 03/11/2004 | WO2004019903A1 Buccal, polar and non-polar spray or capsule containing drugs fortreating metabolic disorders |
| 03/11/2004 | WO2004019886A2 Methods for up-regulating antigen expression in tumors |
| 03/11/2004 | WO2004019884A2 Agents and methods for enhancing bone formation |
| 03/11/2004 | WO2004019881A2 Hypocretin administration as a treatment for obesity |
| 03/11/2004 | WO2004019880A2 Aw755252-interacting proteins and use thereof |
| 03/11/2004 | WO2004019878A2 Adzymes and uses thereof |
| 03/11/2004 | WO2004019876A2 Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| 03/11/2004 | WO2004019866A2 Compositions and methods for treating cardiovascular disease |
| 03/11/2004 | WO2004019865A2 Amelioration of effects of cigarette smoke |
| 03/11/2004 | WO2004019863A2 Combination therapy for treatment of fibrotic disorders |
| 03/11/2004 | WO2004019857A2 Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor |
| 03/11/2004 | WO2004019761A2 Methods of treating age-related defects and diseases |
| 03/11/2004 | WO2004019758A2 Methods of treating idiopathic pulmonary fibrosis |
| 03/11/2004 | WO2004019685A1 Use of proteases for decomposing allergens |
| 03/11/2004 | WO2004009815A3 Silencing hybrid gene expression |
| 03/11/2004 | WO2004007544A3 Components of the presenilin-complex |
| 03/11/2004 | WO2004007537A3 Modified adenoviral fiber with ablated to cellular receptors |
| 03/11/2004 | WO2004004705A3 Pharmaceutical formulations for preparing drink products |
| 03/11/2004 | WO2004003217A8 Glutathione production |
| 03/11/2004 | WO2003106618A3 Cancer therapy by modulating cdc42-activity |
| 03/11/2004 | WO2003099862A8 Export and modification of (poly)peptides in the lantibiotic way |
| 03/11/2004 | WO2003095662A3 Simultaneous detection of two analytes produced by a cell under the influence of a putative agent using a pin coated assay system |
| 03/11/2004 | WO2003094840A3 Induction of antigen specific immunologic tolerance |
| 03/11/2004 | WO2003093449A3 Methods for delivery of nucleic acids |
| 03/11/2004 | WO2003086308A3 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 03/11/2004 | WO2003084342A3 Method and dietary composition for improving lipid digestibility |
| 03/11/2004 | WO2003072767A3 Regulation of human lipase |
| 03/11/2004 | WO2003072737A3 Biological inhibitions induced by contact inhibitory factor |
| 03/11/2004 | WO2003072128A8 Methods and compositions for treating bone or cartilage defects |
| 03/11/2004 | WO2003071268A3 Method for discovering pharmacologically active substances |
| 03/11/2004 | WO2003070966A3 RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 03/11/2004 | WO2003069346A3 Diagnostic method for stroke |
| 03/11/2004 | WO2003068261A3 Means and methods for altering the motility of the gastrointestinal tract |
| 03/11/2004 | WO2003066587A3 Piperidine or pyrrolidine derivatives having an aminoacyl substituted side chain as melancortin-4 receptor agonists |
| 03/11/2004 | WO2003066585A3 Polymer-based compositions for sustained release |
| 03/11/2004 | WO2003066003A3 Anti-pathogen treatements |
| 03/11/2004 | WO2003062410A3 Torero protein |
| 03/11/2004 | WO2003059946A3 Genetic polymorphisms predicting cardiovascular disease and medication efficacy |
| 03/11/2004 | WO2003059395A3 Antisense compounds directed against human csf-1 |
| 03/11/2004 | WO2003056010A3 An antisense strategy to modulate estrogen receptor response (er. alpha. and/or er. beta.) |
| 03/11/2004 | WO2003055908A3 Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
| 03/11/2004 | WO2003054141A3 Sperm-specific cation channel, catsper2, and uses therefor |
| 03/11/2004 | WO2003049669A3 Methods, devices, and preparations for intervertebral disc treatment |
| 03/11/2004 | WO2003047532A3 Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition |
| 03/11/2004 | WO2003046007A3 Treatment of micro-organism infection |
| 03/11/2004 | WO2003042247A3 Modified anti-tnf alpha antibody |
| 03/11/2004 | WO2003040337A3 Polyamide modulators of cox2 transcription |
| 03/11/2004 | WO2003040172A3 Methods and reagents for peptide-bir interaction screens |
| 03/11/2004 | WO2003038441A3 Screening methods based on cited family proteins |
| 03/11/2004 | WO2003037368A3 Smad7 inhibitors for the treatment of cns diseases |
| 03/11/2004 | WO2003035051A3 The use of proton sequestering agents in drug formulations |
| 03/11/2004 | WO2003033535A3 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 03/11/2004 | WO2003029288A3 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 03/11/2004 | WO2003027671A3 Apoptosis |
| 03/11/2004 | WO2003027229A3 Antisense modulation of rip2 expression |
| 03/11/2004 | WO2003026479A3 Methods of suppressing microglial activation |
| 03/11/2004 | WO2003024398A3 Treatment of sepsis with tafi |
| 03/11/2004 | WO2003024384A3 Improved methods for treatment with viral vectors |
| 03/11/2004 | WO2003020213A3 Methods and compositions for treating inflammatory disorders |
| 03/11/2004 | WO2003018799A3 Modulators of bone homeostasis identified in a high-throughput screen |
| 03/11/2004 | WO2003018618A3 Catalysis of the cis/trans isomerisation of secondary amide peptide compounds |
| 03/11/2004 | WO2003014306A3 Antisense modulation of cholesteryl ester transfer protein expression |
| 03/11/2004 | WO2003013431A3 Compositions and methods for the therapy and diagnosis of breast cancer |
| 03/11/2004 | WO2003008548A3 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 03/11/2004 | WO2003006444A3 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity |
| 03/11/2004 | WO2003004646A3 Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors |
| 03/11/2004 | WO2003004600A3 Improvement of viral uptake into cells and tissues |
| 03/11/2004 | WO2003000203A3 Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling |
| 03/11/2004 | WO2002101026A8 Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms |
| 03/11/2004 | WO2002083856A3 Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof |
| 03/11/2004 | WO2002083709A3 Kinases and phosphatases |
| 03/11/2004 | WO2002083074A3 Methods for the treatment of hepatic disorders |
| 03/11/2004 | WO2002079441A3 Secreted proteins |
| 03/11/2004 | WO2002079434A3 Transgenic mice containing kir3.3 potassium channel gene disruptions |
| 03/11/2004 | WO2002077191A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/11/2004 | WO2002074919A3 Protein-protein interactions |
| 03/11/2004 | WO2002070594A8 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| 03/11/2004 | WO2002068602A3 Methods for modulating g2a receptor activity |